Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial
Primary resultResult — go to the resultAdjusted odds ratio 3.76 95% CI 2.09–6.75Authors' conclusion
In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension.
Study context
- Population
- Primary care patients with left ventricular hypertrophy (LVH) on prior echocardiogram, no established cardiomyopathy and no antihypertensive treatment, Mass General Brigham, 2023–2024
- Participants
- 648 patients
- Comparison
- Population health coordinator-led LVH notification and clinical support pathway vs control
- Interventionn = 326
- Controln = 322reference
- Primary endpoint
- Initiation of an antihypertensive medication
- Follow-up
- 12 months
Methodological details2-arm, pragmatic
- 2-arm
- Pragmatic
Primary result
As reported in the abstract
Adjusted odds ratio
3.76
95% CI 2.09–6.75
P < 0.001
Events by treatment group
Interventionvs Control
adjusted OR 3.76 (95% CI 2.09–6.75); P < 0.001
Secondary outcomes
| Outcome | Adjusted OR (95% CI) | P value | |
|---|---|---|---|
| New hypertension diagnosis | 4.43 (2.36–8.33) | P < 0.001 | |
| 0.10.31310Adjusted odds ratio (log scale) |
Cardiomyopathy diagnosis
- No significant difference between groups
Original publication
Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial. JAMA Cardiol. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →